Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 28, 2024 08:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference

NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...
March 25, 2024 08:30 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows activity in M1 macrophages, natural...
March 18, 2024 08:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024

“Fully Engaging The Human Immune System To Cure Disease,” Featuring CEO, Jeffrey MecklerRegistration now open at INDPMarch2024.TribePublic.com NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) --...
March 13, 2024 07:30 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiating Multi-Dosing for patients with solid tumors NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics,...
March 04, 2024 07:30 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

• Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort • Single dose cohort data...
February 15, 2024 08:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...
February 08, 2024 08:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...
January 04, 2024 08:00 ET | Source: Indaptus Therapeutics

European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform...
November 06, 2023 16:01 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023...
November 06, 2023 08:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to...